Inhibition of Stroma-Driven T-cell Exclusion and Exhaustion in Pancreatic Ductal Adenocarcinoma via CXCR4 and PD-1 Inhibition
By
Alina Deipenbrock
Lina Hofer
Ben E. Wilmes
Timur Cetin
Irene Esposito
Dirk Weyhe
Johannes Stegmaier
Nicole E. Teusch
July 21, 2026
Clinical Scorecard: Inhibition of Stroma-Driven T-cell Exclusion and Exhaustion in Pancreatic Ductal Adenocarcinoma via CXCR4 and PD-1 Inhibition
At a Glance
Category Detail
Condition Pancreatic ductal adenocarcinoma (PDAC) Key Mechanisms Immunosuppressive tumor microenvironment (TME), T-cell exclusion, T-cell exhaustion Target Population Patients with pancreatic ductal adenocarcinoma Care Setting Oncology and immunotherapy research
Key Highlights
PDAC characterized by a desmoplastic TME leading to T-cell dysfunction. Stromal CXCL12–CXCR4 axis enhances T-cell exclusion from the tumor. PD-1 blockade with pembrolizumab partially restores T-cell function. 3D PDAC spheroids effectively model TME-driven immune suppression. Patient-derived spheroids replicate patient-specific T-cell suppression patterns. Guideline-Based Recommendations
Diagnosis
Utilize imaging and biopsy to confirm PDAC diagnosis. Management
Consider immunotherapy options targeting PD-1 and CXCR4. Monitoring & Follow-up
Regular assessment of T-cell infiltration and exhaustion markers. Risks
High risk of metastasis and poor prognosis associated with PDAC. Patient & Prescribing Data
Patients diagnosed with pancreatic ductal adenocarcinoma.
Inhibition of PD-1 and CXCR4 may improve T-cell responses.
Clinical Best Practices
Incorporate immune profiling in treatment planning for PDAC. Utilize 3D models for preclinical testing of immunotherapeutic strategies. Related Resources & Content
